Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Platelet release in hemophilia.

H Al-Mondhiry1

  • 1Department of Medicine, Pennsylvania State University, College of Medicine, Hershey.

Thrombosis and Haemostasis
|June 3, 1987
PubMed
Summary

Patients with hemophilia exhibit elevated beta-thromboglobulin (BTG) levels, indicating increased platelet activation. This platelet release is linked to disease severity and frequent bleeding, suggesting a sustained hemostasis response.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fibrinogen interaction with human platelets: effect of other coagulation factors, prostaglandins and platelet inhibitors.

Thrombosis research·2010
Same author

Sweet's syndrome without granulocytosis.

International journal of dermatology·1998
Same author

Splenic rupture in afibrinogenemia: conservative versus surgical management.

The American journal of medicine·1995
Same author

Evaluation of the fibrinolytic system in calves implanted with an artificial heart and ventricular assist device.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·1995
Same author

Congenital afibrinogenemia.

American journal of hematology·1994
Same author

Congenital afibrinogenemia and splenic rupture.

The American journal of medicine·1994

Area of Science:

  • Hematology
  • Hemostasis and Thrombosis

Background:

  • Platelet function abnormalities are observed in hemophilia patients.
  • Beta-thromboglobulin (BTG) and platelet factor 4 (PF4) are specific markers of platelet alpha-granule release.

Purpose of the Study:

  • To measure plasma BTG and PF4 levels in hemophiliacs.
  • To investigate the relationship between platelet activation markers and hemophilia severity, bleeding frequency, and treatment.

Main Methods:

  • Plasma BTG and PF4 levels were measured in 72 hemophiliacs.
  • Patients were studied across different clinical conditions and treatment regimens.
  • Levels were compared between stable patients, those with recent bleeding, and healthy controls.

Main Results:

  • Stable hemophiliacs showed significantly elevated BTG levels compared to controls (p = 0.006).
  • Elevated BTG was independent of liver disease, HIV, or AIDS.
  • Recent bleeding episodes markedly increased BTG levels (p = 0.0002), indicating in vivo platelet activation.
  • Increased BTG correlated with disease severity (bleeding frequency, factor concentrate use) but not factor VIII/IX levels.

Conclusions:

  • Hemophilia patients exhibit enhanced platelet alpha-granule release, evidenced by elevated BTG levels.
  • This enhanced platelet release likely reflects sustained hemostatic activation secondary to frequent bleeding in severe hemophilia.
  • Platelet activation markers may serve as indicators of disease activity and severity in hemophilia.

Related Experiment Videos